
OPCH Stock Forecast & Price Target
OPCH Analyst Ratings
Bulls say
Option Care Health is facing temporary headwinds due to changes in insurance plans resulting in delays in patient census, but they are focusing on expanding their advanced practitioner capabilities and leveraging labor to improve margins. While there are setbacks in certain specialty therapies, the company continues to have strong momentum in its acute therapy business, which comes with higher gross margins. Additionally, the recent merger with BioScrip has positioned Option Care Health as a leading player in the home and alternate-site infusion market.
Bears say
Option Care Health is facing a variety of headwinds including a lowered financial guidance for 2026, a steep implied EBITDA ramp in the second half, and the expectation of difficulty in driving 21%-31% core growth without significant events such as competitive exits or procurement T/Ws. With a significant share price drop of 24%, there may be a buying opportunity for investors, but there are also company-specific risks such as potential slowdown in specialty growth and competition leading to margin pressure.
This aggregate rating is based on analysts' research of Option Care Health and is not a guaranteed prediction by Public.com or investment advice.
OPCH Analyst Forecast & Price Prediction
Start investing in OPCH
Order type
Buy in
Order amount
Est. shares
0 shares